Ingredient Guide
Devil's Claw: Benefits, Dosage, and What the Research Says
A research-reviewed look at the southern African root studied for joint and back pain support.
Written by Jessica Medson
Devil's Claw (Harpagophytum procumbens) is a perennial root herb native to the Kalahari Desert of southern Africa whose primary active compounds, the iridoid glycosides harpagoside and harpagide, may help support normal inflammatory balance in joint and connective tissues. A 2006 Cochrane systematic review found strong evidence that daily doses standardized to 50-100 mg harpagoside outperformed placebo for non-specific low back pain, and multiple small randomized trials report comparable short-term symptom relief to conventional NSAIDs for hip and knee osteoarthritis. Evidence is encouraging overall, but most individual trials are small and short-term, so results should be interpreted with appropriate caution.
What Is Devil's Claw?
Devil's Claw (Harpagophytum procumbens) is a perennial flowering plant native to the Kalahari Desert and arid savanna regions of southern Africa, particularly Namibia, Botswana, and South Africa. The striking common name refers to the plant's fruit, which is covered in sharp, claw-like hooks that latch onto the fur and feet of passing animals for seed dispersal. Medicinally, only the plant's secondary storage roots (secondary tubers) are harvested and dried for use in herbal preparations.1
Traditional Use
For centuries, indigenous southern African peoples - including the San, Khoi, and Bantu communities - used Harpagophytum preparations for a broad range of complaints: fever, malaria, digestive upset, wounds, and painful inflammatory conditions such as arthritis and rheumatism. The plant's use spread to Europe in the early 20th century, gaining particular traction in German-speaking countries as a remedy for musculoskeletal discomfort, where it eventually received a formal monograph from Germany's Commission E for the adjunctive therapy of degenerative musculoskeletal conditions.1
The Plant and Its Supply
Namibia remains the world's primary commercial exporter. Commercial demand has raised sustainability concerns: wild harvesting techniques that destroy the entire plant rather than selectively removing secondary tubers have placed populations under pressure in some regions. In 2009, Namibian exports alone were valued at approximately 1.06 million euros.1 Consumers sourcing Devil's Claw responsibly should look for products specifying certified sustainable or cultivated origin.
Standardized root extracts are available in capsule, tablet, and liquid form. Key quality indicators include the stated harpagoside percentage, but research suggests that harpagoside content alone incompletely predicts efficacy - the whole phytocomplex appears to act synergistically, with multiple plant compounds contributing alongside harpagoside.2
How Does It Work? The Active Compounds and Their Mechanisms
The biological activity of Devil's Claw is attributed primarily to a family of compounds called iridoid glycosides - specifically harpagoside, harpagide, and procumbide - along with flavonoids, aromatic acids, and phytosterols. Harpagoside is the most abundant and most extensively studied of these compounds and is used as the primary standardization marker.2
Inhibition of Inflammatory Signaling Pathways
Preclinical research (Tier C - cell and animal studies; human mechanistic confirmation not yet established) shows that harpagoside and whole plant extracts can disrupt multiple pro-inflammatory signaling pathways simultaneously.
- NF-kB pathway: In hepatocyte and macrophage cell lines, harpagoside blocked the movement of NF-kB - a master transcription factor that switches on hundreds of inflammatory genes - from the cytoplasm into the nucleus, while preserving its inhibitory subunit IkappaB-alpha. This downstream effect suppressed production of both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), two enzymes strongly linked to tissue inflammation and pain signaling.3
- AP-1 pathway: A separate line of research found that a standardized ethanol extract dose-dependently inhibited release of TNF-alpha, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), and prostaglandin E2 (PGE2) in human monocytes and macrophage cell lines. The mechanism involved suppression of the AP-1 transcription pathway - distinct from NF-kB - suggesting Devil's Claw may act through several parallel routes rather than a single molecular target.4
Why Whole Extract Matters More Than Isolated Harpagoside
A consistent finding in the mechanistic literature is that pure isolated harpagoside is less potent than equivalent concentrations of the whole plant extract in laboratory models. Harpagoside-free extracts also retain meaningful anti-inflammatory activity, pointing to synergistic interactions among flavonoids, phytosterols, and other phenolic compounds.4 This explains why standardized extracts specifying both total extract weight and harpagoside content are preferable to isolated harpagoside or unstandardized root powder. No controlled human mechanistic study has yet directly confirmed these pathway effects at clinically used doses; the preclinical data provide a plausible biological rationale for the clinical findings but should be interpreted alongside those trials, not in place of them.
Devil's Claw for Joint Discomfort and Mobility
The largest body of human clinical evidence for Devil's Claw relates to osteoarthritis of the hip and knee. Across multiple trials using standardized extracts, researchers have documented meaningful reductions in self-reported pain and functional limitation scores. The evidence base includes observational studies, active-controlled RCTs, and systematic reviews, though individual trial sizes are generally modest.
What the research shows
In a 12-week multicenter drug surveillance study enrolling 75 people with hip or knee osteoarthritis, participants received 2,400 mg/day of an aqueous Devil's Claw extract standardized to 50 mg harpagoside. By week 12, scores on the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) - a validated, widely used composite instrument - had improved by approximately 23-24% across all subscales: pain fell by 23.8%, stiffness by 22.2%, and physical function limitations by 23.1%. Pain on palpation improved by 45.5% and mobility limitations decreased by 35%. Only two minor adverse events (mild digestive complaints) were reported across the entire cohort.5
A 4-month randomized double-blind trial (122 participants) compared Harpagophytum extract (2,610 mg/day) directly against diacerhein - a slow-acting pharmaceutical drug used in osteoarthritis - in patients with hip and/or knee involvement. Both groups achieved comparable improvements in pain scores and Lequesne functional index. Importantly, the Devil's Claw group required significantly less rescue analgesic and anti-inflammatory medication and reported fewer adverse events than the diacerhein group throughout the trial.6
In a more recent 8-week randomized active-controlled trial comparing Teltonal (a standardized Harpagophytum extract) to meloxicam (a prescription-strength NSAID) in 30 knees with mild osteoarthritis, both groups showed statistically significant within-group improvements (p < 0.001) in VAS pain scores, WOMAC, and Oxford Knee Score. There was no statistically significant difference between the two treatments at study end, suggesting a comparable short-term effect for mild disease in this small pilot.7
A 2006 review of 14 clinical trials concluded that higher-quality studies were collectively suggestive of meaningful pain reduction, while highlighting methodological limitations in many individual trials and calling for larger, more rigorously controlled work.8 The overall picture for osteoarthritis is encouraging but not definitive: most trials are underpowered, and preparations vary considerably in extract type and harpagoside content between studies.
Devil's Claw for Low Back Pain
Evidence for Devil's Claw in non-specific low back pain is the most consistently positive in the entire clinical literature for this herb. Notably, the evidence earned a "strong" rating in a Cochrane systematic review - a relatively high bar for any herbal supplement.
What the research shows
The 2006 Cochrane review by Gagnier and colleagues examined multiple controlled trials and concluded that Devil's Claw extract standardized to 50 mg or 100 mg harpagoside daily was better than placebo for short-term pain reduction in non-specific low back pain. The review also found limited evidence of comparable efficacy to low-dose rofecoxib (12.5 mg daily), a COX-2 selective NSAID that was the standard of care at the time.9
An earlier systematic review of 12 trials by Gagnier, Chrubasik, and Manheimer (2004) stratified the evidence by preparation type and dose. It found strong evidence for aqueous extract at 50 mg harpagoside per day and moderate evidence at 100 mg harpagoside per day for short-term management of acute exacerbations of chronic non-specific low back pain. Across double-blind studies reviewed, adverse event rates during Devil's Claw treatment were no higher than during placebo.10
In a randomized double-blind pilot RCT, 88 patients with non-specific low back pain were assigned to either Doloteffin (a proprietary Harpagophytum extract, providing 60 mg harpagoside/day) or rofecoxib (12.5 mg/day) for 6 weeks. Both groups showed roughly 23-26% reductions in Aarhus pain index scores, with no statistically significant difference between them. Adverse event frequency was similar across groups, though events were more clinically severe in the rofecoxib arm. Rescue tramadol use was modestly higher in the Devil's Claw group (21 vs. 13 patients), a finding the authors attributed to the small sample size rather than definitive inferiority.11
These findings represent the primary indication for which European regulatory authorities have historically approved Devil's Claw preparations. Important caveats: virtually all trials addressed acute exacerbations of chronic non-specific low back pain over 4-8 weeks. Evidence for acute back pain, radicular pain, or long-term prevention is absent. Devil's Claw does not replace medical evaluation for new or severe back pain.
Safety, Side Effects and Interactions
Overall safety picture: A systematic review analyzing 28 clinical trials that reported adverse event data found that the incidence of adverse events during Devil's Claw treatment was not higher than during placebo treatment in any of the double-blind studies reviewed. When side effects did occur, they were minor and present in approximately 3% of participants, with gastrointestinal complaints - nausea, diarrhea, or abdominal discomfort - as the predominant type.12 Most clinical trials ran for 4-12 weeks; long-term safety data beyond 3 months are limited.
Contraindications
- Stomach or duodenal ulcers: Avoid Devil's Claw. It contains bitter compounds that stimulate gastric acid secretion, and its COX-inhibiting activity may further stress an already compromised gastric lining.
- Gallstones: Use cautiously. Devil's Claw may stimulate bile flow, which could provoke symptoms in people with existing gallbladder disease. Consult a physician before use.
- Pregnancy and breastfeeding: Do not use. Harpagophytum has traditionally been used as a uterotonic agent in some indigenous systems, and no controlled safety data exist for pregnant or breastfeeding women.
- Pediatric populations: No clinical trials have been conducted in children. Avoid use without direct medical supervision.
Drug Interactions
- Warfarin and other anticoagulants (blood thinners): A clinically relevant interaction has been documented. Devil's Claw may inhibit CYP2C9, the liver enzyme responsible for metabolizing warfarin, potentially raising warfarin blood levels and increasing bleeding risk. Case reports of over-anticoagulation have been published.13 Inform your prescriber or pharmacist before using Devil's Claw if you take any anticoagulant or antiplatelet medication.
- NSAIDs and aspirin: Combining Devil's Claw with NSAIDs (ibuprofen, naproxen, meloxicam) may produce additive effects on the gastric lining. Consult a healthcare provider before combining.
- Antidiabetic medications: Preclinical data suggest possible blood-glucose-lowering activity. Monitor blood sugar closely if used alongside insulin or oral diabetes drugs.
- Antiarrhythmic medications: Limited data suggest a possible interaction with heart rhythm drugs. Consult a cardiologist or physician before use if you have a cardiac condition.
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before adding any supplement to your routine, particularly if you have a diagnosed medical condition or take prescription medications.
Devil's Claw Dosage Guide
The following doses are drawn from published clinical trials. Doses are expressed in both total extract weight and harpagoside equivalent (the standardization marker used across studies). Always follow the label of your specific product, as extract concentration varies by manufacturer.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| Non-specific low back pain (acute exacerbation of chronic pain) | 1,200-2,400 mg standardized root extract daily (providing 50-100 mg harpagoside) | Divided into 2-3 doses taken with meals | 50 mg harpagoside/day rated 'strong evidence' vs. placebo in 2006 Cochrane review; 60 mg used in pilot RCT vs. rofecoxib |
| Hip or knee osteoarthritis support | 2,400-2,610 mg standardized root extract daily (providing 50-100 mg harpagoside) | Divided into 2-3 doses taken with meals | Used across 8-week to 4-month trials; meaningful changes typically observed by weeks 4-8 |
| General joint comfort maintenance | 600-1,200 mg standardized root extract daily | Once or twice daily with food | Lower end of studied range; no clinical trial data specifically for prevention or long-term maintenance; limit use to 12 weeks unless supervised by a healthcare provider |
Long-term safety data beyond 12 weeks are limited. Do not exceed studied doses without medical guidance. Dose equivalency depends on the harpagoside percentage of your specific extract - check your supplement label.
Devil's Claw Evidence at a Glance
The following table summarizes the strength and nature of human clinical evidence for Devil's Claw across its main studied outcomes.
| Outcome | Evidence Tier | What Studies Show | Key Limitation |
|---|---|---|---|
| Non-specific low back pain | Tier A (Cochrane systematic review + RCTs) | Daily doses standardized to 50-100 mg harpagoside outperform placebo; one pilot RCT found comparable relief to 12.5 mg rofecoxib over 6 weeks | Trials are short-term (4-8 weeks); pilot-scale sample sizes; no long-term data |
| Hip and knee osteoarthritis | Tier A-B (RCTs + observational) | ~23% WOMAC improvement vs. baseline in observational study; comparable to meloxicam and diacerhein in small head-to-head RCTs | Most RCTs are underpowered; heterogeneous extract preparations; some trials lack adequate blinding |
| Anti-inflammatory biomarkers (NF-kB, COX-2, TNF-alpha, PGE2) | Tier C (preclinical only) | Harpagoside and whole extracts suppress NF-kB and AP-1 pathways, reducing COX-2, TNF-alpha, IL-6, IL-1b, and PGE2 in cell and animal models | Cell and animal data only; controlled human mechanistic studies have not been published |
| Analgesic activity | Tier C (preclinical only) | Anti-nociceptive effects documented in rodent pain models; whole extract more potent than isolated harpagoside | Animal data only; mechanism in living humans not confirmed in controlled studies |
Tier A = human RCT or meta-analysis. Tier B = human observational. Tier C = animal or cell-based data only; human evidence not established.
Frequently Asked Questions
What is Devil's Claw good for?
The most clinically studied uses are non-specific low back pain and osteoarthritis of the hip and knee. A 2006 Cochrane review found strong evidence that doses standardized to 50-100 mg harpagoside daily outperformed placebo for short-term back pain relief. Evidence for joint discomfort is encouraging but based on smaller, less rigorous trials. Traditional uses include fever, digestive complaints, and general pain support.
How much Devil's Claw should I take per day?
Most clinical trials used standardized extracts providing 50-100 mg of harpagoside daily, delivered as 1,200-2,610 mg of total root extract in two or three divided doses with meals. Start at the lower end (around 50 mg harpagoside equivalent) and evaluate response after 4-6 weeks. Product concentration varies, so check your supplement label for the exact harpagoside content.
Does Devil's Claw actually work for joint pain?
Evidence is moderately promising. Multiple small randomized trials found Devil's Claw performed comparably to NSAIDs (meloxicam, rofecoxib) and the drug diacerhein in reducing pain and improving mobility scores, without the higher adverse-event burden seen with conventional drugs. However, most trials are short-term and underpowered. Results should be interpreted cautiously - this is a supplement with supporting clinical data, not a proven pharmaceutical.
How long does it take for Devil's Claw to work?
Clinical trials typically reported meaningful symptom changes within 4-8 weeks of consistent daily use. There are no published data supporting acute pain relief within hours, as Devil's Claw appears to work as a slow-acting herb rather than an immediate analgesic. Allow at least 4 weeks before evaluating efficacy at a given dose.
Is Devil's Claw safe?
Generally considered safe at studied doses for up to 12 weeks. A systematic review of 28 clinical trials found adverse event rates were no higher than placebo. The most common side effects are mild gastrointestinal complaints in about 3% of users. Avoid if you have stomach ulcers, gallstones, are pregnant or breastfeeding, or take warfarin or other blood thinners without medical supervision.
What are Devil's Claw side effects?
The most commonly reported side effects are mild gastrointestinal symptoms - nausea, diarrhea, stomach pain, or abdominal fullness. These occurred in approximately 3% of participants across 28 analyzed clinical trials, at rates no higher than placebo. Serious adverse events are rare at standard doses in the published literature. Allergic reactions are possible but not well documented.
Can I take Devil's Claw with ibuprofen or other NSAIDs?
Combining Devil's Claw with NSAIDs such as ibuprofen or naproxen is not recommended without medical supervision. Both may inhibit COX enzymes, potentially increasing risk of gastrointestinal irritation with combined use. Clinical interaction data are limited. If you take regular NSAID therapy, discuss adding any herbal supplement with your healthcare provider before starting.
Is Devil's Claw anti-inflammatory?
In a preclinical sense, yes. Cell-based studies show that harpagoside and whole Devil's Claw extracts inhibit NF-kB and AP-1 activation, suppress TNF-alpha, IL-6, and IL-1b release, and reduce COX-2 activity and prostaglandin E2 levels. These are key mediators of tissue inflammation. Direct confirmation of these mechanisms in controlled human studies has not yet been published.
Who should not take Devil's Claw?
Devil's Claw should be avoided by people with stomach or duodenal ulcers, active gallstone disease, or who are pregnant or breastfeeding. Those taking warfarin, heparin, or other anticoagulants should not use it without direct physician guidance due to a documented drug interaction risk. People on antidiabetic or antiarrhythmic medications should consult a healthcare provider before use.
What should I look for when buying a Devil's Claw supplement?
Look for products specifying both total extract weight and harpagoside content per serving - clinical trials used extracts providing 50-100 mg harpagoside daily. Aqueous or ethanolic standardized extracts are preferable to unstandardized root powder. Third-party testing for purity and label accuracy (USP, NSF, or Informed Sport certification) further reduces risk of quality variation between products.
Shop Devil's Claw
HealthFare Devil's Claw supplements
Scientific References
- 1.Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N Devil's Claw - a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. J Ethnopharmacol. 2012. PubMed: 22940241Human observational
- 2.Menghini L, Recinella L, Leone S, Chiavaroli A, Cicala C, Brunetti L, Vladimir-Knezevic S, Orlando G, Ferrante C Devil's claw (Harpagophytum procumbens) and chronic inflammatory diseases: A concise overview on preclinical and clinical data. Phytother Res. 2019. PubMed: 31273865Human observational
- 3.Huang TH, Tran VH, Duke RK, Tan S, Chrubasik S, Roufogalis BD, Duke CC Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol. 2006. PubMed: 16203115Preclinical (animal / cell)
- 4.Fiebich BL, Munoz E, Rose T, Weiss G, McGregor GP Molecular targets of the antiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFalpha and COX-2 gene expression by preventing activation of AP-1. Phytother Res. 2012. PubMed: 22072539Preclinical (animal / cell)
- 5.Wegener T, Lupke NP Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytother Res. 2003. PubMed: 14669250Human observational
- 6.Leblan D, Chantre P, Fournie B Harpagophytum procumbens in the treatment of knee and hip osteoarthritis. Four-month results of a prospective, multicenter, double-blind trial versus diacerhein. Joint Bone Spine. 2000. PubMed: 11143915Clinical (RCT / meta-analysis)
- 7.Farpour HR, Rajabi N, Ebrahimi B The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial. Evid Based Complement Alternat Med. 2021. PubMed: 34712343Clinical (RCT / meta-analysis)
- 8.Brien S, Lewith GT, McGregor G Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. J Altern Complement Med. 2006. PubMed: 17212570Clinical (RCT / meta-analysis)
- 9.Gagnier JJ, van Tulder M, Berman B, Bombardier C Herbal medicine for low back pain. Cochrane Database Syst Rev. 2006. PubMed: 16625605Clinical (RCT / meta-analysis)
- 10.Gagnier JJ, Chrubasik S, Manheimer E Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med. 2004. PubMed: 15369596Clinical (RCT / meta-analysis)
- 11.Chrubasik S, Model A, Black A, Pollak S A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology (Oxford). 2003. PubMed: 12509627Clinical (RCT / meta-analysis)
- 12.Vlachojannis J, Roufogalis BD, Chrubasik S Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain. Phytother Res. 2008. PubMed: 18236448Clinical (RCT / meta-analysis)
- 13.Izzo AA, Di Carlo G, Borrelli F, Ernst E Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005. PubMed: 15676159Human observational